Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

Chen, Jiaqi; Zhang, Ding; Yuan, Ying

doi:10.1007/s10238-022-00873-6

Cited by 10 publications

(10 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed that adding anti‐PD1 treatment to HAIC combined with lenvatinib extended the mOS of patients with advanced HCC by 7 months 31 . Moreover, significant survival benefits from the combination of anti‐PD1 treatment with TACE have been confirmed by multiple studies 32,33 …”

Section: Discussionmentioning

confidence: 97%

“…31 Moreover, significant survival benefits from the combination of anti-PD1 treatment with TACE have been confirmed by multiple studies. 32,33 Currently, combined immunotherapy of atezolizumab plus bevacizumab or durvalumab plus tremelimumab was significantly superior to standard sorafenib in prognosis according to these two clinical trials. Indeed, TKIs sequential therapy has been more effective in improving F I G U R E 3 Forestplot based on overall survival (A) and progression-free survival (B) of each subgroup.…”

Section: Discussionmentioning

confidence: 99%

“… 31 Moreover, significant survival benefits from the combination of anti‐PD1 treatment with TACE have been confirmed by multiple studies. 32 , 33 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis

Li,

Liu,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

PurposeTo investigate the clinical efficacy and safety of combination therapy of hepatic arterial infusion chemotherapy (HAIC) and anti‐programmed cell death protein‐1 (PD‐1) therapy in the treatment of advanced hepatocellular carcinoma (HCC).MethodsIn this retrospective clinical research, from March 2018 to December 2019, 1158 HCC patients categorized as BCLC stage C were reviewed for eligibility. We utilized propensity score matching (PSM) to mitigate initial disparities between the groups. The evaluation of the best tumor response was conducted in accordance with mRECIST 1.1 criteria. The difference in survival outcomes including overall survival (OS), progression‐free survival (PFS), and objective response rate (ORR) between groups were compared.ResultsFollowing the eligibility review, 453 patients underwent a combined treatment of HAIC with PD1 inhibitors (HAIC‐PD1 group), while 221 patients received HAIC monotherapy (HAIC group) met the inclusion criteria and were finally enrolled in this study. In the entire cohort, the HAIC‐PD1 group exhibited significantly prolonged overall survival (median overall survival: 40.4 months vs. 9.7 months, p < 0.001) and progression‐free survival (median progression‐free survival: 22.1 months vs. 5.8 months, p < 0.001). By propensity score, patients were matched according to baseline differences, resulting in all 442 patients in group HAIC‐PD1 (n = 221) and group HAIC (n = 221). After PSM adjustment, as well, the survival of the HAIC‐PD1 group was still distinctly longer than the HAIC group (median overall survival time, 40.4 months vs 9.7 months, p < 0.001; median progression‐free survival, 22.1 months vs 5.7 months, p < 0.001). Univariate and multivariable analysis demonstrated that AFP level, metastasis, and therapeutic schedule were independent predictive factors for overall survival.ConclusionThe combination therapy of HAIC and PD1 inhibitors successfully extended OS to advanced HCC patients and could be a better choice than HAIC monotherapy.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis

Li,

Liu,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…HCC is a malignancy characterized by its ability to stimulate angiogenesis, facilitating the acquisition of an adequate blood flow through the formation of new blood vessels [ 8 , 9 ]. This process is commonly referred to as tumor angiogenesis and typically involves two primary mechanisms: angiogenesis, the generation of new blood vessels, and vasculogenesis, the enlargement of existing blood vessels.…”

Section: Discussionmentioning

confidence: 99%

Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma

Liu,

Wei,

Nie

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Objective Our study was to investigate the impact of taurolactone, a novel anti-tumor and anti-angiogenic drug, on AGGF1, an angiogenic factor, and angiogenesis mimicry in patients diagnosed with hepatocellular carcinoma (HCC). Methods A total of 120 HCC patients were enrolled from the Department of Oncology and Hepatobiliary Surgery at our hospital between May 2021 and December 2022. HCC diagnoses were confirmed through imaging or tissue biopsy for all patients. The age of patients ranged from 37 to 72 years, with an average age of 64.29 ± 4.58 years. These participants were divided equally into two groups: the control group and the observation group, each consisting of 60 individuals. While the control group received standard drug treatment, the observation group was administered taurolactone treatment. Before being included in the study, all participants or their legal representatives provided signed informed consent. Patient demographic information was collected through a questionnaire survey. ELISA was used to measure the levels of VEGF and AGGF1 in patients following treatment. Western blot was applied to assess the protein expression of PDGF, Angiopoietin, and AGGF1. MRI imaging technology was utilized to assess the perfusion characteristics of tumor blood vessels in patients. Tumor vessel density was compared between patients using ultrasonography. We also conducted a comparison between the two groups in terms of progression-free survival and overall survival. Results General patient information between the two groups showed no significant differences (P > 0.05). Of note, the observation group exhibited greatly lower levels of VEGF and AGGF1 compared to the control group (P < 0.05). Moreover, the levels of PDGF, Angiopoietin, and AGGF1 protein expression were significantly reduced in the observation group compared to the control group (P < 0.05). In terms of tumor perfusion, the observation group displayed lower average and maximum perfusion volumes in tumor blood vessels compared to the control group (P < 0.05). Additionally, the observation group demonstrated delayed peak times and arrival times of tumor blood vessels in comparison to the control group (P < 0.05). Furthermore, the density of tumor blood vessels was notably lower in the observation group compared to the control group (P < 0.05). Patients in the observation group had longer progression-free survival and overall survival than the control group (P < 0.05). Conclusion In HCC patients, our study highlighted the potential efficacy of taurolactone treatment as it effectively inhibited angiogenic factors and angiogenesis mimicry, ultimately leading to an improved prognosis for these patients.

show abstract

“…Further research into tumor-related mechanisms has gradually validated the potential for enhanced conversion when drugs with different reported antitumor mechanisms are used in combination ( 63 , 64 ). This rationale has led to the proposal of combining LRT and systemic therapy, which has resulted in higher conversion rates in uHCC ( 65 ).…”

Section: Discussionmentioning

confidence: 99%

Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis

Li,

Zhang,

Wang

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the opportunity to undergo radical treatment and achieve long-term survival. Despite accumulating evidence regarding the efficacy of conversion therapy, the optimal treatment approach for such therapy remains uncertain. Lenvatinib (LEN) has shown efficacy and tolerable rates of adverse events (AEs) when applied in combination with immune checkpoint inhibitors (ICIs) or locoregional therapy (LRT) over the past decade. Therefore, the present meta-analysis was performed to systematically assess the safety and efficacy of LEN-based treatment regimens in conversion therapies for uHCC. Data on outcomes, including the conversion rate, objective response rate (ORR), disease control rate (DCR) and AE incidence in patients with uHCC, were collected. A systematic literature search was performed using MEDLINE, Embase, Web of Science and Cochrane Library databases, up to the date of September 1, 2023. In total, 16 studies, encompassing a total of 1,650 cases of uHCC, were included in the final meta-analysis. The pooled conversion rates for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were calculated to be 0.04 (95% CI, 0.00–0.07; I 2 =77%), 0.23 (95% CI, 0.16–0.30; I 2 =66%), 0.14 (95% CI, 0.10–0.18; I 2 =0%) and 0.35 (95% CI, 0.23–0.47; I 2 =88%), respectively. The pooled ORRs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were found to be 0.45 (95% CI, 0.23–0.67; I 2 =96%), 0.49 (95% CI, 0.39–0.60; I 2 =78%), 0.43 (95% CI, 0.24–0.62; I 2 =88%) and 0.69 (95% CI, 0.56–0.82; I 2 =92%), respectively. The pooled DCRs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were observed to be 0.77 (95% CI, 0.73–0.81; I 2 =23%), 0.82 (95% CI, 0.69–0.95; I 2 =90%), 0.67 (95% CI, 0.39–0.94; I 2 =94%) and 0.87 (95% CI, 0.82–0.93; I 2 =67%), respectively. The pooled grade ≥3 AEs for LEN alone, LEN + ICI, LEN + LRT and LEN + ICI + LRT were 0.25 (95% CI, 0.14–0.36; I 2 =89%), 0.43 (95% CI, 0.34–0.53; I 2 =23%), 0.42 (95% CI, 0.19–0.66; I 2 =81%) and 0.35 (95% CI, 0.17–0.54; I 2 =94%), respectively. These findings suggested that LEN-based combination strategies may confer efficacy and acceptable tolerability for patients with uHCC. In particular, LEN + ICI, with or without LRT, appears to represent a highly effective conversion regimen, with an acceptable conversion rate and well-characterized safety profile.

show abstract

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

Cited by 10 publications

References 91 publications

Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis

Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis

Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma

Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis

Contact Info

Product

Resources

About